Emerging treatments for rheumatoid arthritis: Update
Publication
, Journal Article
Savage, C; St. Clair, EW; Sundy, JS
Published in: Consultant
August 1, 2005
Early treatment with disease-modifying anti-rheumatic drugs (DMARDs)-alone or in combination-can prevent joint damage and minimize disability. Until recently, the DMARDs used predominantly in patients with rheumatoid arthritis had been methotrexate, sulfasalazine, and hydoxychloroquine. Older DMARDs such as gold, D-penicillamine, and azathioprine have fallen out of favor because of their long-term toxicities or modest benefit. Six newer DMARDs-leflunomide, etanercept, infliximab, adalimumab, rituximab, and anakinra-have greatly expanded the current treatment options.
Duke Scholars
Published In
Consultant
ISSN
0010-7069
Publication Date
August 1, 2005
Volume
45
Issue
9
Start / End Page
984 / 995
Related Subject Headings
- General & Internal Medicine
Citation
APA
Chicago
ICMJE
MLA
NLM
Savage, C., St. Clair, E. W., & Sundy, J. S. (2005). Emerging treatments for rheumatoid arthritis: Update. Consultant, 45(9), 984–995.
Savage, C., E. W. St. Clair, and J. S. Sundy. “Emerging treatments for rheumatoid arthritis: Update.” Consultant 45, no. 9 (August 1, 2005): 984–95.
Savage C, St. Clair EW, Sundy JS. Emerging treatments for rheumatoid arthritis: Update. Consultant. 2005 Aug 1;45(9):984–95.
Savage, C., et al. “Emerging treatments for rheumatoid arthritis: Update.” Consultant, vol. 45, no. 9, Aug. 2005, pp. 984–95.
Savage C, St. Clair EW, Sundy JS. Emerging treatments for rheumatoid arthritis: Update. Consultant. 2005 Aug 1;45(9):984–995.
Published In
Consultant
ISSN
0010-7069
Publication Date
August 1, 2005
Volume
45
Issue
9
Start / End Page
984 / 995
Related Subject Headings
- General & Internal Medicine